{"id":4810,"date":"2019-10-24T16:43:44","date_gmt":"2019-10-24T15:43:44","guid":{"rendered":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/?p=4810"},"modified":"2021-06-15T16:51:55","modified_gmt":"2021-06-15T15:51:55","slug":"aducanumab-how-excited-should-we-be","status":"publish","type":"post","link":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/aducanumab-how-excited-should-we-be\/","title":{"rendered":"Aducanumab – how excited should we be?"},"content":{"rendered":"\n

Joel Petch, Senior Lecturer in Mental Health and Clinical Science, discusses the potential of a new drug to assist in the treatment of Alzheimer\u2019s disease.<\/strong><\/em><\/p>\n\n\n\n\n\n\n\n

This week, Biogen, an American pharmaceutical company filed an application to the US Food and Drug Administration<\/a> (FDA) for the drug Aducanumab to be licenced as a therapeutic agent for Alzheimer\u2019s disease<\/a> (AD). If approved, Aducanumab would become the first medication licenced for the treatment of AD in the past decade; and approval in the US could lead the way to UK approval.<\/p>\n\n\n\n

AD remains the leading cause of dementia – an umbrella term for progressive and irreversible brain conditions with marked tissue loss within the brain. <\/p>\n\n\n\n

Current treatment options for AD include evidence-based pharmacological agents, including acetylcholinesterase inhibitors and glutamatergic antagonists; although, currently approved medications are considered to slow the progression of the disease, as opposed to reverse the disease and associated clinical decline, as has been stated by Biogen regarding Aducanumab.<\/p>\n\n\n\n

So, is\nAducanumab the AD miracle drug that we\u2019ve been waiting for? Possibly, but probably\nnot, and here\u2019s why.<\/p>\n\n\n\n

Aducanumab is, actually, not a new drug; and a number of previous trials have failed to demonstrate meaningful improvements, when compared to placebo. This lack of response to Aducanumab actually led to Biogen\u2019s own phase three trails being discontinued in early 2019, which makes the latest claims from Biogen even more surprising. <\/p><\/blockquote>\n\n\n\n

This has\nbeen attributed to a higher than initially thought dose being required, as well\nas the duration of exposure to Aducanumab being influential. This was only\ndetected following an extensive, retrospective data trawl by Biogen. This has\nbeen referred to, by Biogen, as due to an incorrect analysis earlier within the\nyear. However, if the drug is as effective as is now being stated, the\ndiscrepancy between the interpretations of data is somewhat surprising.<\/p>\n\n\n\n

If the data provided by Biogen, which still requires robust and independent statistical analysis, does demonstrate that Aducanumab offers clearance of the accumulations of A\u03b2- this could be a significant advancement within our understanding of what is without a doubt a devastating disease. It is exciting that there is renewed scientific and pharmaceutical interest within the area of AD, something which has reduced over recent years, often considered to be due to the complexity of AD. <\/p>\n\n\n\n

Currently, whilst we are awaiting further analysis of the data and Biogen\u2019s formal application to the FDA, it may be prudent not to get too excited regarding the potential of Aducanumab; an easy trap to fall in to, particularly given the paucity of optimism related to new drugs within the field over recent years. For now, it is important to be optimistic, but we must be realistic also. <\/p>\n\n\n\n

Joel Petch is a senior lecturer in mental health and clinical science within the Faculty of Health and Wellbeing. Joel’s clinical interests include the interface between physical and mental ill-health, psychoneuroimmunology, psychopharmacology, and structural neuroimaging. Joel can be founding discussing most things neuro-related on Twitter @joelpetch<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Joel Petch, Senior Lecturer in Mental Health and Clinical Science, discusses the potential of a new drug to assist in the treatment of Alzheimer\u2019s disease.<\/p>\n","protected":false},"author":151654,"featured_media":4837,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5,3902],"tags":[3093,3094,3105,3098,3102],"class_list":["post-4810","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-research","tag-aducanumab","tag-biogen","tag-dementia","tag-pharmaceutical-company","tag-us-food-and-drug-administration"],"acf":[],"aioseo_notices":[],"authorName":"Emma Grafton-Williams","featuredImage":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-content\/uploads\/sites\/437\/2019\/10\/brain-scan.jpg","postExcerpt":"Joel Petch, Senior Lecturer in Mental Health and Clinical Science, discusses the potential of a new drug to assist in the treatment of Alzheimer\u2019s disease.","_links":{"self":[{"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/posts\/4810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/users\/151654"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/comments?post=4810"}],"version-history":[{"count":9,"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/posts\/4810\/revisions"}],"predecessor-version":[{"id":7661,"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/posts\/4810\/revisions\/7661"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/media\/4837"}],"wp:attachment":[{"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/media?parent=4810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/categories?post=4810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.canterbury.ac.uk\/expertcomment\/wp-json\/wp\/v2\/tags?post=4810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}